A probiotic marketed as LactoSpore by Sabinsa was found to be a safe and effective adjunct therapy for the treatment of diarrhea in a clinical study published in Frontiers in Pediatrics.
The heat-stable Weizmannia coagulans (Bacillus coagulans) MTCC 5856 was studied as an adjunct treatment in 110 non-hospitalized children between the ages of 1 and 10 with diarrhea.
Children received either 400 million spores per day of LactoSpore combined with an oral hydration solution (ORS) and zinc, or a placebo plus ORS and zinc for five days. The added probiotic was linked to significantly faster recovery, reduced diarrhea frequency, better perceived efficacy score, and greater improvements in dehydration status.
As a result, the authors concluded that the LactoSpore combined with standard treatment was more effective than standard treatment alone.
“All age groups need beneficial bacteria in their gut, and kids especially, so it’s important to add to the range of clinical research for common childhood conditions,” said Shaheen Majeed, global CEO and managing director of Sabinsa. “This clinical [study] proves improvement in efficacy by the inclusion of LactoSpore with the standard treatment of care of oral hydration solution and zinc.”
